NASDAQ: RNAZTranscode Therapeutics Inc Stock
$1.15+0.26 (+29.21%)
Updated May 17, 2024
RNAZ Price
$1.15
Fair Value Price
N/A
Market Cap
$7.62M
52 Week Low
$0.42
52 Week High
$309.60
P/E
-0.01x
P/B
1.66x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$17.06M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.59
Operating Cash Flow
-$17M
Beta
1.24
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
RNAZ Overview
TransCode Therapeutics Incorporated is a biopharmaceutical company that develops drugs and diagnostics for treating and identifying metastatic disease. The company's lead therapeutic candidate is TTX-MC138, a preclinical stage product for the treatment of metastatic cancer. TransCode Therapeutics was incorporated in 2016 and is headquartered in Boston, MA.
Zen Score
–
Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RNAZ scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RNAZ is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RNAZ is good value based on its book value relative to its share price (1.66x), compared to the US Biotechnology industry average (6.01x)
P/B vs Industry Valuation
RNAZ is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RNAZ due diligence checks available for Premium users.
Be the first to know about important RNAZ news, forecast changes, insider trades & much more!
RNAZ News
Valuation
RNAZ price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.01x
Industry
8.47x
Market
30.97x
RNAZ price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.66x
Industry
6.01x
RNAZ is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RNAZ's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.3M
Profit Margin
0%
RNAZ's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$7.3M
Liabilities
$2.7M
Debt to equity
0.59
RNAZ's short-term assets ($6.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RNAZ's short-term assets ($6.71M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RNAZ's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.9M
Investing
-$3.8k
Financing
$6.1M
RNAZ's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RNAZ vs Biotech Stocks
Transcode Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.